Research presented at SABCS 2024 highlighted efforts to expand treatment options for early breast cancer as well as ...

The opportunity for innovation in the local private health sector is enormous, especially in lower-income markets. Early ...

US-based pharmaceutical company MSD has reported positive results from two Phase III trials of doravirine/islatravir (DOR/ISL ...

Broad enrollment criteria appear to have scuttled the trial, which was designed to test whether ctDNA could identify patients ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced the discontinuation of the clinical ...

Merck to discontinue phase 3 KeyVibe-003 & KeyVibe-007 trials of vibostolimab and favezelimab FDCs with pembrolizumab in certain patients with NSCLC: Rahway, New Jersey Wednesday, ...

China National Medical Products Administration (NMPA) has approved MSD’s KEYTRUDA for treating certain non-small cell lung cancer (NSCLC).

We recently compiled a list of the 12 Best Weight Loss Stocks to Buy According to Hedge Funds. In this article, we are going ...

New research revealed tumor mutational burden was linked to improved event-free survival with pembrolizumab in early TNBC, ...

The results come two months after Merck shared positive results from the phase 3 KEYNOTE-689 trial of Keytruda as a ...

Ltd. to support its expansion efforts in Thailand. This collaboration aims to enhance market coverage of MSD's vaccines and ...

At the 79th session of the United Nations General Assembly, leaders called for member states to take decisive actions to ...